IMB 101 - IMBiologics
Alternative Names: IMB-101 - IMBiologics; NAV-240; OX40LxTNFα bispecific antibody - IMBiologics; OXTIMALatest Information Update: 09 Sep 2024
At a glance
- Originator HK inno.N
- Class Anti-inflammatories; Bispecific antibodies
- Mechanism of Action OX40 ligand inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rheumatoid arthritis
Most Recent Events
- 09 Sep 2024 Pharmacodynamics data from preclinical trial in Rheumatoid arthritis released by IMBiologics (IMBiologics pipeline; September 2024).
- 17 Jun 2024 Navigator Medicines in-licenses IMB 101 from IMBiologics
- 13 Dec 2023 IMBiologics plans a phase I trial in USA for Rheumatoid Arthritis (IV) in December 2023 (NCT06181786)